2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial RunwayBusiness Wire • 09/12/23
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune TherapiesBusiness Wire • 09/12/23
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare ConferenceBusiness Wire • 09/06/23
2seventy bio Reports Second Quarter Financial Results and Recent Operational ProgressBusiness Wire • 08/14/23
2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023Business Wire • 08/08/23
2seventy Bio Stock Crumbles After A Patient Dies In Its Pediatric Cancer StudyInvestors Business Daily • 06/14/23
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid LeukemiaBusiness Wire • 06/14/23
2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid LeukemiaBusiness Wire • 05/19/23
2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies PortfolioBusiness Wire • 05/17/23
2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023Business Wire • 05/11/23
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/04/23
2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressBusiness Wire • 05/03/23
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual MeetingBusiness Wire • 05/02/23
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A ProgramBusiness Wire • 05/01/23
Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/29/23